Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
3 May 2013
HER2-positive breast cancer patients prefer faster subcutaneous administration of Herceptin to IV
15 March 2013
BRIC countries' breast cancer market to see 8% annual growth to 2017
14 February 2013
San Antonio breast cancer meeting highlights
10 December 2012
Pfizer and Roche hope to score with ESMO presentations, notes GlobalData
25 September 2012
75% of US oncologists prescribe Pfizer's Xalkori just 10 months after the drug's launch
21 June 2012
UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin
27 April 2012
NICE views breast cancer drugs from GSK and Roche too expensive
14 February 2012
Clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015
5 February 2012
Roche signs up to $490 million accord with PTC Thera for SMA program; and deal with Galena
30 November 2011
Stada Arz and Richter link up to develop and market two biosimilars: rituximab and trastuzumab
1 September 2011
Roche to start production of Herceptin in Russia
23 June 2011
More NICE rejections, for Roche’s Avastin and Herceptin and GlaxoSmithKline’s Tyverb
15 December 2010
Roche convinces UK’s NICE to recommend Herceptin for metastatic gastric cancer; Novartis fail in higher dose Glivec
25 November 2010
US FDA approves Genentech/Roche’s Herceptin for HER2-positive metastatic stomach cancer; Roche amends deal with Biogen
22 October 2010
GlaxoSmithKline sues Roche/Genentech alleging Herceptin patent infringements; updates on Relovair Ph II development with Theravance
23 September 2010
PDL BioPharma sues Roche’s Genentech over royalties
2 September 2010
Regulatory briefs: Shire’s Vpriv cleared in Europe; Menactra for toddlers; Updates for Novartis and Roche
27 August 2010
Switzerland’s Roche eyes up China’s potential
2 March 2010
Europe’s CHMP backs Sanofi Pasteur’s Humenza and GSK’s Votrient; gives opinions on other products
22 February 2010
Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs
3 February 2010
US FDA clears new uses for two GlaxoSmithKline drugs; Tykerb and Lamictal; GSK set to announce 3,000 job cuts
1 February 2010
European approval for Merck & Co’s Elonva and new indication for Roche’s Herceptin; Roche sets up Singapore research hub
28 January 2010
US FDA clears restart of Roche Ph III Avastin trials; other strong data presented at San Antonio meeting
14 December 2009
Targeted agents will drive gastric cancer drug market to nearly $1.5 billion in 2018
5 November 2009
UK’s NICE won’t fund GSK’s breast cancer drug Tyverb; USA’s CDC backs Cervarix and Merck & Co’s Gardasil for boys
22 October 2009
Roche nine-month 2009 sales boosted by strong Tamiflu showing
15 October 2009
Seattle Genetics hires new commercial chief, promotes legal exec
14 October 2009
Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will erode $8.2 billion in US and European sales in 2018
17 September 2009
Wyeth presents strong combo drug data at ASCO
29 May 2009
Roche's T-DM1 shrinks tumors in Ph II study
28 May 2009
Stock Commentary - Europe - week to May 18, 2009
21 May 2009
PDL BioPharma swings to profit on cost-cuts
11 May 2009
Stock Commentary - New York week to March 30, 2009
2 April 2009
GSK appeals UK's NICE refusal for Tyverb
30 March 2009
Strong Ph III data for Herceptin in stomach cancer
23 March 2009
"90% four-year survival" with Herceptin
16 March 2009
PDL returns to profit on sales up 31%
16 March 2009
Generex treats first patient with AE37 vacc
9 March 2009
UPDATE: Dutch NGO's CT claims rebutted by GSK and AZ
16 February 2009
Dutch NGO's CT claims rebutted by GSK
16 February 2009
Roche's profit falls 5% on lower Tamiflu sales
9 February 2009
Wyeth's neratinib plus Herceptin yields 60% PFS rate
22 December 2008
Novartis' Afinitor may overcome Herceptin resistance; Ph I study
22 December 2008
Genentech licenses more ImmunoGen TAP tech
15 December 2008
Ph II study of ImClone's IMC-A12 starts enrolling patients
24 November 2008
PDL out of red ahead of biotech spin-off
17 November 2008
UK HER2 patients miss out on best treatment
27 October 2008
UK's NHS must attack wonder drug "fiction"
20 October 2008
UK volume price plan for GSK's Tyverb
11 August 2008
Japan stock market week to July 28, 2008
4 August 2008
Roche's 1st-half net profit sees downturn
28 July 2008
GSK's Tyverb gets European approval
23 June 2008
Herceptin works in different disease stages
9 June 2008
Avastin + Herceptin HER2 study initiated
9 June 2008
Roche to lift stake in Chugai to 59.9%
2 June 2008
Daiichi Sankyo takes over U3 Pharma
26 May 2008
PDL's 1st-qtr 2008 net loss triples to $62M
26 May 2008
GSK's Tykerb enters Ph III breast cancer trial
19 May 2008
Delay to EU approval of GSK
31 March 2008
Japan stock market week to March 10, 2008
17 March 2008
Roche's new CEO commits to p-med
10 March 2008
Japan drug approval recommendations
11 February 2008
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
